Akari Therapeutics amends CEO pay package for Abizer Gaslightwala

Akari Therapeutics, Plc disclosed in an 8-K that on September 29, 2026, it signed an amendment to the Chief Executive Officer Agreement it originally entered into with Abizer Gaslightwala on March 14, 2025.

The amendment raises Gaslightwala's annual base salary from $475,000 to $625,000, effective August 18, 2026, with 10 percent of that amount, or $62,500, to be paid in restricted stock units under the company's 2023 Equity Incentive Plan rather than cash over the twelve months starting August 18, 2026.¹ Those RSUs were granted on the date of the amendment and are scheduled to vest quarterly over the following year, but vesting is contingent on shareholders approving an increase to the number of American Depositary Shares reserved under the 2023 Plan; if that approval is not obtained, the RSUs will be forfeited and the company will instead make cash adjustments so Gaslightwala still receives his full base salary.¹

The amendment also lifts Gaslightwala's bonus target. His target annual bonus moves from 50 percent of base salary to 55 percent, which the company said brings his combined target salary and bonus to roughly $970,000.¹ Separately, he was granted options to buy 174,000 ADSs under the 2023 Plan dated August 18, 2026, set to vest monthly over four years with vesting treated as having started March 18, 2026, again subject to shareholder approval of the expanded share reserve.¹

The 8-K describes this as only a summary, with the full amendment filed as Exhibit 10.1.¹ The filing was signed by Interim Chief Financial Officer Kameel Farag and dated October 1, 2026.